中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

6 records (took 0.012 seconds)

    Stabilized Receptor Polypeptides and Uses Thereof
    2.
    发明申请
    Stabilized Receptor Polypeptides and Uses Thereof 审中-公开
    稳定受体多肽及其用途

    公开(公告)号：US20160137718A1

    公开(公告)日：2016-05-19

    申请号：US15004375

    申请日：2016-01-22

    Applicant: Amgen Inc.

    Inventor： Jeonghoon Sun ,  Lei-Ting Tony Tam ,  Mark Leo Michaels ,  Thomas Charles Boone ,  Rohini Deshpande ,  Yue-Sheng Li ,  Huiquan Han

    IPC: C07K14/71

    CPC classification number: C07K14/71 ,  A61K38/00 ,  C07K14/495

    Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.

    Abstract translation: 本发明提供稳定的活化素IIB受体多肽和能够结合并抑制活化素A，肌生成抑制素或GDF-11的活性的蛋白质。 本发明还提供能够产生稳定的多肽和蛋白质的多核苷酸，载体和宿主细胞。 还提供了治疗肌肉消瘦疾病和代谢紊乱的组合物和方法。

    Continuous manufacturing process for bispecific antibody products
    3.
    发明授权
    Continuous manufacturing process for bispecific antibody products 有权

    公开(公告)号：US12227571B2

    公开(公告)日：2025-02-18

    申请号：US16770441

    申请日：2018-12-11

    Applicant: AMGEN INC.

    Inventor： Chetan Goudar ,  Rohini Deshpande ,  Natalia Gomez ,  Hedieh Barkhordarian ,  Yan Wang

    IPC: C07K16/28 ,  C07K16/30 ,  C12M1/00 ,  C12N5/00 ,  B01F101/44 ,  C12M3/00

    Abstract: The present invention provides a continuous upstream manufacturing process for the production of bispecific antibody products, which comprise at least two binding domains. The process comprises at least the steps of (i) providing in a perfusion bioreactor at least one mammalian cell culture, which is capable of expressing the bispecific antibody product, (ii) growing the mammalian cell culture at a first perfusion rate until a set point viable cell density is reached, and (iii) maintaining perfusion culture at a second perfusion rate, wherein the bispecific antibody product concentration in the bioreactor is kept below a threshold value. The bispecific antibody product is then subject to subsequent downstream processing. Moreover, the invention provides a bispecific antibody product produced by the continuous upstream manufacturing process.

    CONTINUOUS MANUFACTURING PROCESS FOR BISPECIFIC ANTIBODY PRODUCTS
    5.
    发明申请
    CONTINUOUS MANUFACTURING PROCESS FOR BISPECIFIC ANTIBODY PRODUCTS 有权

    公开(公告)号：US20210163592A1

    公开(公告)日：2021-06-03

    申请号：US16770441

    申请日：2018-12-11

    Applicant: AMGEN INC

    Inventor： Chetan Goudar ,  Rohini Deshpande ,  Natalia Gomez ,  Hedieh Barkhordarian ,  Yan Wang

    IPC: C07K16/28 ,  C07K16/30

    Abstract: The present invention provides a continuous upstream manufacturing process for the production of bispecific antibody products, which comprise at least two binding domains. The process comprises at least the steps of (i) providing in a perfusion bioreactor at least one mammalian cell culture, which is capable of expressing the bispecific antibody product, (ii) growing the mammalian cell culture at a first perfusion rate until a set point viable cell density is reached, and (iii) maintaining perfusion culture at a second perfusion rate, wherein the bispecific antibody product concentration in the bioreactor is kept below a threshold value. The bispecific antibody product is then subject to subsequent downstream processing. Moreover, the invention provides a bispecific antibody product produced by the continuous upstream manufacturing process.

Patent Agency Ranking